Clinical trials: Metastatic Dedifferentiated Liposarcoma
Uveal Melanoma, Melanoma
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Trial name
- NCT05607095
- Testing
- Lifileucel (LN-144/LN-145)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liposarcoma, Dedifferentiated
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336, a selective enzyme blocker, in patients with…
- Trial name
- NCT05580588
- Testing
- SPH4336
- Where
- 9 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to…
- Conditions
- Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT05694871
- Testing
- Palbociclib, Cemiplimab, Magnetic Resonance Imaging
- Where
- 194 sites in United States
- Volunteers
- 77 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Tumors, Sarcoma
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib. This is a Phase 1, open-label, dose-escalation, dose-expansion, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum…
- Conditions
- Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT03604783
- Testing
- TP-1287
- Where
- 10 sites in United States
- Volunteers
- 74 people
- Sponsor
- Sumitomo Pharma America, Inc.
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated…
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
- Trial name
- NCT06422806
- Testing
- Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin
- Where
- 269 sites in United States, Canada and 1 more
- Volunteers
- 365 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body (metastatic) or cannot be removed by…
- Conditions
- Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma
- Trial name
- NCT02500797
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 651 sites in United States
- Volunteers
- 164 people
- Sponsor
- National Cancer Institute (NCI)
Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Liposarcomas are soft tissue sarcomas most frequent. We distinguish three subtypes on the basis of their histological and cytogenetic characteristics: well-differentiated liposarcoma / dedifferentiated, myxoid liposarcoma and /…
- Trial name
- APLIPO (NCT01876043)
- Testing
- plitidepsin
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Institut Bergonié
Sarcoma, Advanced Sarcoma
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.
- Conditions
- Sarcoma, Advanced Sarcoma, High Grade Sarcoma, Leiomyosarcoma
- Trial name
- NCT04242238
- Testing
- DCC-3014, Avelumab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Dedifferentiated Liposarcoma
Ph II Cabazitaxel DD Liposarcoma
Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50 histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct genetic, pathological and clinical profiles, and varying…
- Trial name
- NCT01913652
- Testing
- Cabazitaxel
- Where
- 11 sites in Belgium, France and 2 more
- Volunteers
- 42 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Dedifferentiated Liposarcoma, Soft Tissue Sarcoma
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced).
- Conditions
- Dedifferentiated Liposarcoma, Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma
- Trial name
- NCT05886634
- Testing
- Etrumadenant, Zimberelimab
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
This phase II trial investigates how well oleclumab and durvalumab work in treating patients with sarcoma that has come back (recurrent) or does not respond to treatment (refractory) or has spread to other places in the body…
- Conditions
- Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma
- Trial name
- DOSa (NCT04668300)
- Testing
- Durvalumab, Oleclumab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
This phase I/II trial tests the side effects and best dose of abemaciclib when added to gemcitabine and compares the effectiveness of that treatment to the usual treatment of gemcitabine with docetaxel for the treatment of…
- Conditions
- Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma
- Trial name
- NCT06498648
- Testing
- Abemaciclib, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Conventional Chondrosarcoma, Myxoid Liposarcoma
Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease…
- Conditions
- Conventional Chondrosarcoma, Myxoid Liposarcoma, Mesenchymal Chondrosarcoma, Dedifferentiated Chondrosarcoma
- Trial name
- NCT02821507
- Testing
- sirolimus and cyclophosphamide
- Where
- 7 sites in Netherlands, Spain
- Volunteers
- 70 people
- Sponsor
- Leiden University Medical Center
Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in…
- Conditions
- Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma, Metastatic Sarcoma
- Trial name
- NCT05711615
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors.
- Trial name
- NCT06578624
- Testing
- SA53-OS (phase 1), SA53-OS (phase 2)
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Lamassu Bio Inc